乳腺癌血清cerbB2的检测及其临床意义的任务书任务：撰写一篇关于乳腺癌血清cerbB2的检测及其临床意义的论文。要求：1.综合各类文献，介绍乳腺癌血清cerbB2的检测方法、临床应用、诊断意义、疗效预测等，2.分析cerbB2检测在乳腺癌诊疗中的优点和限制，3.探讨cerbB2检测未来的发展方向和应用前景，4.需要深入阐述cerbB2检测在乳腺癌早期筛查和治疗决策中的重要性。参考文献：1.RossJS,SlodkowskaEA,SymmansWF,PusztaiL,RavdinPM,HortobagyiGN.TheHER-2receptorandbreastcancer:tenyearsoftargetedanti-HER-2therapyandpersonalizedmedicine.Oncologist.2009;14:320–368.2.RugoHS.ThechangingroleofHER2statusinbreastcancer.CurrOncolRep.2010;12:163–170.3.HarrisL,FritscheH,MennelR,etal.AmericanSocietyofClinicalOncology2007updateofrecommendationsfortheuseoftumormarkersinbreastcancer.JClinOncol.2007;25:5287–5312.4.DuffyMJ,DugganC.Theroleofserummarkersinthedetectionofcancer.AnnClinBiochem.2011;48:530–541.5.LønningPE.HER2-positivebreastcancer:anewtherapeutictarget.EurJCancer.2008;44:2457–2463.6.HudisCA.Trastuzumab—mechanismofactionanduseinclinicalpractice.NEnglJMed.2007;357:39–51.7.BaselgaJ,TripathyD,MendelsohnJ,etal.PhaseIIstudyofweeklyintravenoustrastuzumab(Herceptin)inpatientswithHER2/neu-overexpressingmetastaticbreastcancer.SeminOncol.1999;26(4Suppl12):78–83.8.GoldhirschA,WoodWC,CoatesAS,GelberRD,ThürlimannB,SennHJ;Panelmembers.Fulltext]Strategiesforsubtypes—dealingwiththediversityofbreastcancer:highlightsoftheSt.GallenInternationalExpertConsensusontheprimarytherapyofearlybreastcancer2011.AnnOncol.2011;22(8):1736-47.doi:10.1093/annonc/mdr304.Epub2011Jul6.Review.PubMedPMID:21733760.9.NationalComprehensiveCancerNetwork,Guidelinesforbreastcancer,version2.2013.10.WolffAC,HammondME,HicksDG,DowsettM,McShaneLM,AllisonKH,etal.Recommendationsforhumanepidermalgrowthfactorreceptor2testinginbreastcancer.ArchPatholLabMed.2014;138(2):241-56.doi:10.5858/arpa.2013-0953-SA.Erratumin:ArchPatholLabMed.2014May;138(5):607.PubMedPMID:24476585;PubMedCentralPMCID:PMC4163743.